Ignite Creation Date:
2025-12-18 @ 9:27 AM
Ignite Modification Date:
2025-12-23 @ 9:56 PM
Study NCT ID:
NCT04073147
Status:
None
Last Update Posted:
2022-01-19 00:00:00
First Post:
2019-08-26 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
Sponsor:
None
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-05-12
Start Date Type:
ACTUAL
Primary Completion Date:
2021-11-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-11-25
Completion Date Type:
ACTUAL
First Submit Date:
2019-08-26 00:00:00
First Submit QC Date:
None
Study First Post Date:
2019-08-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-01-18 00:00:00
Last Update Post Date:
2022-01-19 00:00:00
Last Update Post Date Type:
ACTUAL